((自动化翻译由路透提供，请见免责声明 ))
路透法兰克福10月25日 - 赛诺菲 财务总监周五表示，该公司不会受到诺和诺德 控股股东收购合同药品生产商康泰伦特<Catalent (link) 的决定的影响，并补充说这笔交易对其竞争对手是有意义的。
"赛诺菲首席财务官弗朗索瓦-格扎维埃-罗杰（Francois-Xavier Roger）在第三季度财报发布后的媒体电话会议上说："他们迫切需要产能，所以这对他们来说是有意义的， (link)。
他补充说，鉴于减肥药的需求非常旺盛，诺和诺德为获得产能付出了 "非常沉重的代价"。
瑞士制药商罗氏 (link) <ROG.S]周三与同行礼来<LLY.N]一样，对计划中的康泰伦特收购表示担忧，称这可能会打击蓬勃发展的减肥药行业的竞争。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.